Prognostic Model Developed, Validated Externally for Prostate Cancer-Specific Mortality
Add Drugs.com as a trusted source on Google to see more of our health news and information in your Google Search results.
- Tap the button to open Google's source settings.
- Tick the box next to Drugs.com.
- You can change it anytime in your Google settings.
Requires a signed-in Google account.
WEDNESDAY, Jan. 14, 2026 -- In a study published online Jan. 13 in the Annals of Internal Medicine, a prognostic model for prostate cancer-specific mortality (PCSM) was developed and externally validated.
Patrick Lewicki, M.D., from the University of Michigan in Ann Arbor, and colleagues developed and externally validated a novel prognostic model for risk for PCSM after a prostate-specific antigen (PSA) test and compared it to existing tools. Prognostic model development was conducted in the prostate cancer screening group of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (33,339 male patients aged 55 to 74 years) and external validation was performed in a Veterans Affairs population undergoing PSA testing (174,787 patients). The model's predicted outcome was PCSM at a specified time point.
The researchers found that the area under the receiver operating characteristic curve (AUC) at 29.5 years from screening was 0.666 versus 0.643 for a previously validated prostate biopsy risk model (Prostate Biopsy Collaborative Group [PBCG]) in the model development cohort. The AUC at 20 years from screening was 0.776 and 0.749 for the PLCO and PBCG models, respectively, in the external validation cohort.
"We designed and externally validated a prediction model for risk stratification of patients at the point of PSA screening," the authors write. "Future work will determine the clinical impact of integrating this tool within primary care workflows."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2026 HealthDay. All rights reserved.
Read this next
Recommendations Updated for Management of Tinnitus
WEDNESDAY, Oct. 21, 2026 -- Updated recommendations are presented for the management of tinnitus in a clinical practice guideline issued by the American Academy of...
CGM Beneficial for Adults With Type 2 Diabetes Not on Insulin
WEDNESDAY, Oct. 21, 2026 -- Continuous glucose monitoring (CGM) leads to a greater reduction in glycated hemoglobin (HbA1c) levels than routine care for adults with type 2...
AACR: Younger Adults Less Likely to Have Discussed CRC Screening With Clinician
WEDNESDAY, Oct. 21, 2026 -- Newly eligible younger adults are less likely to have discussed colorectal cancer (CRC) screening with their clinician compared with their older...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Drugs.com Podcast
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
